论文部分内容阅读
目的:探讨长春瑞滨联合卡铂化疗对晚期肺癌的治疗效果和安全性。方法:选取我院肿瘤科收治的晚期肺癌患者60例,根据不同治疗方案分为实验组与对照组,每组各30例患者。比较两组患者治疗前后的CEA、CA50、CYFRA21-1水平、白细胞计数及T淋巴细胞亚群CD4+、CD8+水平的变化。结果:治疗前,两组患者的CEA、CA50、CYFRA21-1水平、白细胞计数及T淋巴细胞亚群CD4+、CD8+水平比较均无统计学差异(P>0.05)。治疗后,实验组的CEA、CA50、CYFRA21-1、CD8+水平均明显低于对照组,而白细胞计数及T淋巴细胞亚群CD4+、CD4+/CD8+水平均显著高于对照组,差异均具有统计学意义(P<0.05)。结论:与放疗相比,长春瑞滨联合卡铂化疗能显著提高晚期肺癌的疗效,且不降低患者的细胞免疫。
Objective: To investigate the efficacy and safety of vinorelbine plus carboplatin in the treatment of advanced lung cancer. Methods: Sixty patients with advanced lung cancer admitted to our department of oncology were selected and divided into experimental group and control group with 30 patients in each group according to different treatment regimens. The changes of CEA, CA50, CYFRA21-1 levels, leukocyte count and T-lymphocyte subsets CD4 + and CD8 + levels before and after treatment were compared between the two groups. Results: Before treatment, the levels of CEA, CA50 and CYFRA21-1, the white blood cell count and the levels of CD4 + and CD8 + of T lymphocyte subsets were not significantly different between the two groups (P> 0.05). After treatment, the levels of CEA, CA50, CYFRA21-1 and CD8 + in the experimental group were significantly lower than those in the control group, while the levels of white blood cell count and T-lymphocyte subsets CD4 + and CD4 + / CD8 + were significantly higher than those in the control group Significance (P <0.05). Conclusion: Compared with radiotherapy, vinorelbine combined with carboplatin can significantly improve the efficacy of advanced lung cancer, and does not reduce cellular immunity in patients.